Creutzfeldt-Jakob disease: Reflections on the risk from blood product therapy

Haemophilia

Volumn 13, Issue SUPPL. 5, 2007, Pages 33-40

  Brown, P ^a,b,c  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b Fondation Alliance BioSécure   (France)

^c NONE   (United States)

Author keywords

Blood infectivity; Creutzfeldt Jakob disease; Prion disease; Transmissible spongiform encephalopathy

Indexed keywords

BLOOD CLOTTING FACTOR 8; PRION PROTEIN;

ARTICLE; BLOOD DONOR; BLOOD FILTRATION; BLOOD TRANSFUSION; COLUMN CHROMATOGRAPHY; CREUTZFELDT JAKOB DISEASE; FUNGUS TRANSMISSION; HUMAN; INCUBATION TIME; INFECTION RISK; NANOFILTRATION; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; RISK REDUCTION;

ANIMALS; BIOLOGICAL PRODUCTS; BLOOD COAGULATION FACTORS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CREUTZFELDT-JAKOB SYNDROME; DISEASE TRANSMISSION, HORIZONTAL; HUMANS; PRION DISEASES; RISK;

EID: 37149043763     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01572.x     Document Type: Article

References (32)

1. Brown P. Blood infectivity in the transmissible spongiform encephalopathies. Chapter 4 In: Turner ML, ed. Creutzfeldt-Jakob Disease: Managing the Risk of Transmission by Blood, Plasma, and Tissues. Bethesda, MD: AABB Press, 2006: 95-118.
2. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-6.
3. Gregori L, Lambert BC, Gurgel PV et.al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion 2006; 46: 1152-61.
4. Bons N, Lehmann S, Mestre-Frances N, Dormont D, Brown P. Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion 2002; 42: 513-6.
5. Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: Persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983; 41: 154-61.
6. Brown P, Cervenakova L, McShane LM, Barber P, Drohan WN. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood products do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
7. Cervenakova L, Yakovleva O, McKenzie C et.al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003; 43: 1687-94.
8. Holada K, Vostal JG, Theisen PW, MacAuley C, Gregori L, Rohwer RG. Scrapie infectivity in hamster blood is not associated with platelets. J Virol 2002; 76: 4649-50.
9. Llewelyn CA, Hewitt RE, Knight RS et.al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
10. Peden AH, Head MW, Ritchie DE, Bell JE, Ironside JW. Autopsy detection of pre-clinical vCJD transmission following blood transfusion from a PRNP codon 129 heterozygote. Lancet 2004; 364: 527-9.
11. Wroe SJ, Pal S, Durrenajaf S et.al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet 2006; 368: 2061-7.
12. Health Protection Agency (Health Protection Report, Vol 1, no 3, 26 January 2007. Available at: http://www.hpa.org.uk/hpr/archives/2007/ news2007/news0307.htm (accessed 10 October 2007).
13. Hilton DA, Ghani AC, Conyers L et.al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-9.
14. Perron H, Dupin M, Cecillon S et.al. A Novel Immunoassay for the Detection of Resistant Prion Protein (PrPres) in Human Plasma. The Prion 2005 Abstract Book (Oral 48, p 61) available at: http://www.neuroprion.net/en/ev_p05_abstracts.html (accessed 10 October 2007).
15. Pan T, Sethi J, Nelsen C et.al. Detection of misfolded prion protein in blood using conformationally sensitive peptides. Transfusion 2007; 47: 1418-25.
16. Heye N, Hensen S, Müller N. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1994; 343: 298-9.
17. Zou S, Notari IV, Fuji K et.al. An update on the Creutzfeldt-Jakob disease look-back study. Presentation at the AABB Annual Meeting and TXPO, 15-18 October 2005, Seattle, WA.
18. Hewitt PE, Llewelyn CA, MacKenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfurion: Results of the UK transfusion medicine epidemiological review study. Vox Sang 2006; 91: 1-10.
19. van Duijn CM, Delasnerie-Lauprêtre N, Masullo C et.al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. Lancet 1998; 351: 1081-5.
20. Wilson K, Code C, Ricketts M. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: Systematic review of case-control studies. Br Med J 2000; 321: 17-9.
21. Sowemimo-Coker S, Kascsak R, Kim A et.al. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukocyte reduction filter. Transfusion 2005; 45: 1839-44.
22. Gregori L, Gurgel PV, Lathrop JT et.al. Reduction of infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368: 2226-30.
23. Foster PR. Removal of TSE agents from blood products. Vox Sang 2004; 87(Suppl. 2): 8-10.
24. Gregori L, Maring JA, MacAuley C et.al. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 2004; 32: 1-10.
25. Flan B, Aubin J-T. Evaluation de l'effiacitédes procédés de purification des protéines plasmatiques àéliminer les agents transmissibles non conventionnels. Virologie 2005; 9: S45-56.
26. Brown P. Blood infectivity, processing, and screening tests in transmissible spongiform encephalopathy. Vox Sang 2005; 89: 63-70.
27. Souci JM, Jackson D, Evatt B. The occurrence of hemophilia in the United States. Am J Hematol 1998; 59: 288-94.
28. Evatt B, Austin E, Barnhart L et.al. Surveillance for Creutzfelt-Jakob disease among persons with hemophilia. Transfusion 1998; 38: 817-20.
29. Jacquemot C, Cuche C, Dormont D, Lazarini F. High incidence of scrapie induced by repeated injections of subinfectious prion doses. J Virol 2005; 79: 8904-8.
30. FDA TSEAC Meeting, 2006. Topic I: FDA's risk assessment for variant Creutzfeldt-Jakob disease (vCJD) potentially associated with the use of US licensed human plasma-derived Factor VIII (pdFVIII, Anti-Hemophilic Factor) products, and potential public health service responses. Available as PDF file at the following FDA website: http://google2.fda.gov/search?output=xml_no_dtd&oe=&lr= &proxystylesheet=FDA&client=FDA&site=FDA&getfields= &q=variant+CJD+risk+assessment&as=Searchusda.
31. Minor P, Brown P. Diagnostic tests for CJD for ante-mortem screening. Chapter 5 In: Turner ML, ed. Creutzfeldt-Jakob Disease: Managing the Risk of Transmission by Blood, Plasma, and Tissues. Bethesda, MD: ABBA Press, 2006: 119-48.
32. Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006; 313: 92-4.